S

Surgical Science Sweden AB
OTC:SUSRF

Watchlist Manager
Surgical Science Sweden AB
OTC:SUSRF
Watchlist
Price: 5.2 USD 4% Market Closed
Market Cap: $265.3m

Wall St Price Targets

SUSRF Price Targets Summary
Surgical Science Sweden AB

Wall Street analysts forecast SUSRF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUSRF is 6.92 USD with a low forecast of 6.05 USD and a high forecast of 9.33 USD.

Lowest Forecast
Price Target
6.05 USD
16% Upside
Average Forecast
Price Target
6.92 USD
33% Upside
Highest Forecast
Price Target
9.33 USD
79% Upside
Surgical Science Sweden AB Competitors:
Price Targets
UMBF
UMB Financial Corp
17% Upside
XPEL
Xpel Inc
27% Upside
CMTG
Claros Mortgage Trust Inc
38% Upside

Revenue
Forecast

36% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
36% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 10 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 10%.

Gross Profit
Forecast

29% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
29% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 10 years, the compound annual growth rate for Gross Profit has been 29%. The projected CAGR for the next 5 years is 12%.

Operating Income
Forecast

49% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss
49% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Over the last 10 years, the compound annual growth rate for Operating Income has been 49%. The projected CAGR for the next 5 years is 30%.

Pre-Tax Income
Forecast

51% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
51% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 10 years, the compound annual growth rate for Pre-Tax Income has been 51%. The projected CAGR for the next 3 years is 33%.

Net Income
Forecast

45% / Year
Past Growth
36% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
45% / Year
Past Growth
36% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 10 years, the compound annual growth rate for Net Income has been 45%. The projected CAGR for the next 5 years is 36%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SUSRF's stock price target?
Price Target
6.92 USD

According to Wall Street analysts, the average 1-year price target for SUSRF is 6.92 USD with a low forecast of 6.05 USD and a high forecast of 9.33 USD.

What is the Revenue forecast for Surgical Science Sweden AB?
Projected CAGR
10%

Over the last 10 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 10%.

What is the Gross Profit forecast for Surgical Science Sweden AB?
Projected CAGR
12%

Over the last 10 years, the compound annual growth rate for Gross Profit has been 29%. The projected CAGR for the next 5 years is 12%.

What is the Operating Income forecast for Surgical Science Sweden AB?
Projected CAGR
30%

Over the last 10 years, the compound annual growth rate for Operating Income has been 49%. The projected CAGR for the next 5 years is 30%.

What is the Pre-Tax Income forecast for Surgical Science Sweden AB?
Projected CAGR
33%

Over the last 10 years, the compound annual growth rate for Pre-Tax Income has been 51%. The projected CAGR for the next 3 years is 33%.

What is the Net Income forecast for Surgical Science Sweden AB?
Projected CAGR
36%

Over the last 10 years, the compound annual growth rate for Net Income has been 45%. The projected CAGR for the next 5 years is 36%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett